The company currently markets ZEGERID Capsules and ZEGERID Powder for Oral Suspension. These products are immediate-release formulations of omeprazole, ...
The company’s current marketing efforts are primarily focused on ZEGERID ® Capsules and Powder for Oral Suspension. These products are immediate-release ...
Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company headquartered in San Diego, today announced GlaxoSmithKline plc has launched ZEGERID ...
The Zegerid products were developed by Santarus Inc. (NASDAQ: SNTS). Santarus and GSK entered into a distribution agreement in November 2007 under which GSK ...
The company's current marketing efforts are primarily focused on ZEGERID(R) Capsules and Powder for Oral Suspension. These products are immediate-release ...
The Zegerid products were developed by Santarus and are the first and only immediate-release oral proton pump inhibitors (PPIs) commercialized in the US. ...
Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company headquartered in San Diego, today announced GlaxoSmithKline plc has launched ZEGERID ...
The Zegerid products were developed by Santarus Inc. (NASDAQ: SNTS). Santarus and GSK entered into a distribution agreement in November 2007 under which GSK ...
The company's current marketing efforts are primarily focused on ZEGERID(R) Capsules and Powder for Oral Suspension. These products are immediate-release ...
Other heartburn drugs include Santarus Inc.'s (SNTX) Zegerid and AstraZeneca's Prilosec. Procter & Gamble (PG) markets an over-the-counter version of ...